Search

Your search keyword '"Escrivá A"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Escrivá A" Remove constraint Author: "Escrivá A" Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
106 results on '"Escrivá A"'

Search Results

3. Changes in entire acute bronchiolitis seasons before, during, and after the COVID-19 pandemic in Spain

7. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

18. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

25. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

26. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs

41. New dinuclear copper complexes incorporating bis(imidazolyl) based ligands and bidentate–monodentate oxalate bridges. Crystal structure and magnetic properties of [Cu2(BIM)2(C2O4)2]·4H2O and [Cu2(BIK)2(C2O4)2] (BIM = bis(2-imidazolyl)methane), BIK = bis(2-imidazolyl)ketone). Exploring magneto-structural correlations

49. 116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa

50. 197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis

Catalog

Books, media, physical & digital resources